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Background: The association between serum alanine aminotransferase (ALT) levels and hepatic insulin resistance
(IR) has been evaluated with the hyperinsulinemic-euglycemic clamp. However, there is no information about the
association of ALT with the Hepatic Insulin Resistance Index (HIRI). The aim of this study was to evaluate the
association between serum ALT levels and HIRI in subjects with differing degrees of impaired glucose metabolism.
Methods: This cross-sectional study included subjects that had an indication for testing for type 2 diabetes mellitus
(T2DM) with an oral glucose tolerance test (OGTT). Clinical and biochemical evaluations were carried out including
serum ALT level quantification. HIRI was calculated for each participant. Correlation analyses and lineal regression
models were used to evaluate the association between ALT levels and HIRI.
Results: A total of 324 subjects (37.6% male) were included. The mean age was 40.4 ± 14.3 years and the mean
body mass index (BMI) was 32.0 ± 7.3 kg/m2. Individuals were divided into 1 of 5 groups: without metabolic
abnormalities (n = 113, 34.8%); with the metabolic syndrome (MetS, n = 179, 55.2%), impaired fasting glucose
(IFG, n = 85, 26.2%); impaired glucose tolerance (IGT, n = 91, 28.0%), and T2DM (n = 23, 7.0%). The ALT (p < 0.001) and
HOMA2-IR (p < 0.001) values progressively increased with HIRI quartiles, while ISI-Matsuda (p < 0.001) progressively
decreased. After adjustment for sex, age, and BMI, we identified a significant correlation between HIRI and ALT in
persons with the MetS (r = 0.22, p = 0.003), IFG (r = 0.33, p < 0.001), IGT (r = 0.37, p < 0.001), and T2DM (r = 0.72,
p < 0.001). Lineal regression analysis adjusting for age, HDL-C, TG and waist circumference (WC) showed an
independent association between ALT and HIRI in subjects with the MetS (beta = 0.07, p = 0.01), IFG (beta = 0.10,
p = 0.02), IGT (beta = 0.09, p = 0.007), and T2DM (beta = 0.31, p = 0.003). This association was not identified in subjects
without metabolic abnormalities.
Conclusions: ALT levels are independently associated with HIRI in subjects with the MetS, IFG, IGT, and T2DM. The
ALT value in these subjects may be an indirect parameter to evaluate hepatic IR.
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The liver is an important organ for glucose metabolism; this
includes glucose uptake, storage, and synthesis [1]. Studies
have shown that nonalcoholic fatty liver disease (NAFLD)
increases the risk for the metabolic syndrome (MetS) [2],
type 2 diabetes mellitus (T2DM), and cardiovascular dis-
eases [3-8]. Serum alanine aminotransferase (ALT) has been
closely correlated with liver fat accumulation [9-11]. There-
fore, this enzyme is commonly used as a biomarker of
NAFLD [12]. In addition, clinical studies have associated
serum ALT levels with insulin resistance (IR), the MetS and
the development of T2DM [13-15].
In the fasting state, the rate of hepatic glucose produc-
tion (HGP) is the main determinant of the fasting glu-
cose concentration. Insulin normally inhibits HGP,
however this suppression is not well achieved in subjects
with hepatic insulin resistance. Therefore, elevated fast-
ing insulin can be considered a surrogate marker of hep-
atic insulin resistance [16,17]. Accurate measurement of
IR requires the use of techniques such as clamps that
are costly, time-consuming, and invasive for use in large
epidemiological or clinical studies. In this context,
a number of simple indexes of IR have been proposed
[18-23]. These indexes include HOMA-2, Matsuda-ISI,
and QUICKI, among others.
A number of studies have reported a positive association
between serum ALT levels and IR using indirect para-
meters such as the intravenous glucose tolerance test,
(OR=3.0 [95% CI 2.2-4.1]), and the homeostasis model
assessment of insulin resistance [HOMA-IR, OR=2.1 (1.5-
2.9)] [3,14]. In the same way, a negative correlation has
been reported between ALT and insulin sensitivity using
the euglycemic hyperinsulinemic clamp (Clamp ISI,
r =−0.44, p <0.001) [15]. The association of ALT with
hepatic insulin sensitivity measured by the euglycemic-
hyperinsulinemic clamp (r= 0.21, p= 0.001) has been deter-
mined [13]. However, there is no information about the
association of ALT with the insulin sensitivity index (ISI)
of Matsuda [24] and HIRI [25]. The aim of the study was
to evaluate whether an independent association exists be-
tween serum ALT levels and HIRI in subjects with differ-
ing degrees of impaired glucose metabolism.
Subjects and methods
A total of 324 subjects fulfilled the selection criteria and
were recruited for this cross-sectional study. The popula-
tion consisted of subjects from the Internal Medicine
and Endocrinology outpatient clinics of the Instituto
Nacional de Ciencias Médicas y Nutrición “Salvador
Zubirán” (INCMNSZ) that received attention between
March 2007 and July 2010. We included individuals of
both genders from 18 to 65 years-old, that had a 75 g oral
glucose tolerance test (OGTT), and at least two risk fac-
tors for T2DM as stated by the American DiabetesAssociation (ADA) [26]. These include: physical inactiv-
ity, a first-degree relative with T2DM, high risk race/eth-
nicity, women with a history of delivering a baby
weighing >4 kg or with a diagnosis of gestational diabetes
mellitus during their pregnancy, arterial hypertension
(blood pressure ≥140/90 mmHg or on therapy for hyper-
tension), HDL cholesterol (HDL-C) level <35 mg/dL
(0.90 mmol/L) and/or a triglyceride level >250 mg/dL
(2.82 mmol/L), women with polycystic ovary syndrome,
A1C ≥5.7%, IGT, or IFG on previous testing, other clin-
ical conditions associated with insulin resistance (e.g., se-
vere obesity, acanthosis nigricans), and a history of
cardiovascular disease. HIRI and Matsuda indexes were
calculated using the glucose and insulin values obtained
every 30 minutes during the OGTT. We defined
impaired fasting glucose (IFG, fasting glucose between
100 and 125 mg/dL), impaired glucose tolerance (IGT,
2 hr glucose value in the OGTT between 140 and
199 mg/dL), and type 2 diabetes (T2DM, fasting glucose
level ≥ 126 mg/dL in two occasions, or glucose ≥ 200 mg/
dL at the 2nd hr of the OGTT) using ADA criteria [26].
The MetS was defined according to the U.S. 2004 Na-
tional Cholesterol Education Program (NCEP) Adult
Treatment Panel III guidelines [27] and modified as
recommended in the latest American Heart Association/
National Heart, Lung, and Blood Institute Scientific State-
ment for fasting glucose and waist circumference [28].
The MetS was defined as the presence of three or more of
the following risk factors: 1) central obesity (waist cir-
cumference ≥80 cm in women and≥ 90 cm in men) 2)
hypertriglyceridemia (fasting triglycerides ≥150 mg/dl
(≥1.69 mmol/l); 3) low HDL cholesterol (HDL cholesterol
<50 mg/dl (<1.29 mmol/l) in women and <40 mg/dl
(1.04 mmol/l) in men); 4) hyperglycemia (fasting glucose
≥100 mg/dl (≥5.6 mmol/l); and 5) arterial hypertension
(sitting blood pressure of 130/85 mmHg or more, taken as
a mean of two readings obtained after a rest of at least
10 min in this position). We excluded subjects with medi-
cations that could influence glucose and insulin values
during the OGTT such as steroids, oral glucose lowering
drugs (such as metformin, sulfonylureas, thiazolidine-
diones, acarbose, dipeptidyl peptidase-4 inhibitors, and gli-
nides), subcutaneous insulin, and thyroid hormones. We
also excluded subjects with other chronic diseases (such
as HIV infection, hepatitis C infection (all subjects that
received a blood transfusion before 1992 were tested for
hepatitis C, other viral markers were not measured), sys-
temic lupus erythematosus, rheumatoid arthritis, seizures,
major depression, use of hepatotoxic drugs (i.e., aceta-
minophen, antibiotics, analgesics, chemotherapy among
others) hospitalization in the past 6 months, active cancer
or under treatment for cancer), and pregnant women. The
population was divided into 5 groups according to the de-
gree of impaired glucose metabolism: 1) without metabolic
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IGT or T2DM; 2) with the MetS; 3) IFG; 4) IGT; and 5)
T2DM. IR was estimated using HOMA2-IR calculator
provided on the web page [18]; insulin sensitivity was esti-
mated with the ISI Matsuda with the formula: 10000/
√(Glucose 0’ x Insulin 0’) x (mean glucose x mean insulin)
[24]. HIRI was evaluated using the formula described by
Abdul-Ghani as follows: √(glucose 0 to 30 [AUC in mg/dl/
hr] x insulin 0–30 [AUC in μU/ml/hr]) [25].
Biochemical and anthropometric measurements
The central laboratory of the INCMNSZ performed all
biochemical laboratory measurements. The measure-
ments were carried out with commercially available
standardized methods. Glucose, total cholesterol, HDL-
cholesterol, and triglycerides were measured using the
Synchron CX analyzer (Beckman Systems, Fullerton
CA). Plasma insulin concentrations were estimated using
a radioimmunoassay method (MEIA, Abbott Laborator-
ies). ALT and aspartate aminotransferase (AST) were
measured using an enzymatic method AU2700 Beckman
Coulter (Fullerton, CA). Anthropometric measurements
were carried out after participants removed their shoes
and upper garments. Body weight was measured with a
mechanical beam scale (Health o meter Inc, Bridgeview IL)
with daily calibration. Body fat was measured with
Quantum Desktop - BIA Analyzer by RJL systems. All sub-
jects were instructed to stand in the center of the scale dur-
ing weight assessment. Height was obtained using the floor
scale’s stadiometer. Height was measured to the nearest
0.5 cm. WC was measured to the nearest 0.1 cm at the level
of the greatest frontal extension of the abdomen between
the bottom of the rib cage and the top of the iliac crest.
BMI was calculated using weight (kg) divided by height
squared (m2). Sitting blood pressure was measured after a
rest of at least 10 min in this position.
Ethics statement
The subanalyses presented in this study are from a
protocol approved by our Human Biomedical Research
Institutional Committee (REF 1650). Written informed
consent was obtained from all subjects. All clinical in-
vestigation was conducted according to the principles
expressed in the Declaration of Helsinki.
Statistical analyses
Normally distributed data as assessed by the
Kolmogorov-Smirnov test were expressed as mean and
standard deviation (±SD) whereas variables with a skewed
distribution were reported as median (interquartil range).
The Pearson chi square test, Student’s unpaired t-test
(normally distributed data), or Mann–Whitney U test
(skewed distribution) was used as appropriate for com-
parisons between the sexes and for comparisons betweensubjects without metabolic abnormalities and subjects
with differing degrees of impaired glucose metabolism.
We divided the population in terms of HIRI quartiles:
0 to 28.2, 28.2 to 35.7, 35.7 to 43.2 and ≥ 43.2. Then,
we compared these quartiles with the ALT and AST
levels, peripheral and hepatic IR indexes, and the clinical
and biochemical variables. One-way ANOVA (normally
distributed data) or Kruskall–Wallis test (skewed distri-
bution) was used for the comparisons between quar-
tiles of the HIRI. Correlation coefficients between HIRI
(adjusted for sex, age and BMI) and the clinical and
biochemical parameters were evaluated with partial cor-
relation analysis in each of the groups. We made six
lineal regression models, one for each of the impaired
glucose metabolism groups, to identify independent fac-
tors associated with HIRI. The variables selected to enter
the regression analyses were those that correlated signifi-
cantly with the HIRI. All reported p values are based on
two-sided tests considering ≤0.05 as significant. All ana-
lyses were performed with SPSS 17.0 (Chicago, IL).
Results
The characteristics of the study population, stratified by
gender and the degree of impaired glucose metabolism
are shown in Table 1. A total of 324 subjects (37.6%
male) were included. The mean age was 40.4 ± 14.3 years
with a BMI of 32.0 ± 7.3 kg/m2. The median (interquartil
range) ALT concentration was 26.0 IU/L (20.0-41.0) with
a HOMA2-IR, ISI Matsuda, and HIRI of 1.4 (0.9-2.0),
3.5 (2.3-5.5), and 36.9 ± 12.1, respectively. A total of 113
subjects (34.8%) without metabolic abnormalities, 179
subjects (55.2%) with the MetS, 85 subjects (26.2%) with
IFG, 91 subjects (28.0%) with IGT, and 23 subjects
(7.0%) with T2DM were evaluated. As is summarized in
Table 1, significant differences were identified in ALT,
HDL-C, and body fat percentage between males and
females in each group.
The baseline characteristics stratified by HIRI levels
are shown in Table 2. In terms of demographic and la-
boratory data, a progressive and significant increment in
weight (p < 0.001), BMI (p < 0.001), WC (p < 0.001), ALT
(p < 0.001), body fat percentage (p < 0.001), insulin
(p < 0.001), HOMA2-IR (p < 0.001) and HIRI (p < 0.001)
were observed. In addition, HDL-C (p < 0.001) and ISI-
Matsuda (p < 0.001) progressively decreased among HIRI
quartiles. Interestingly, a higher level of HIRI and
HOMA2-IR and a lower level of ISI-Matsuda index were
identified among quartiles of ALT (Figure 1).
The partial correlations adjusted for gender, age and BMI
between HIRI and the clinical and biochemical parameters
are shown in Table 3. HIRI levels correlated significantly
with ALT in all subjects with a metabolic diagnosis: MetS
(r =0.22, p=0.003), IFG (r =0.33, p<0.001), IGT (r =0.37,
p< 0.001), and T2DM (r=0.72, p <0.001).

















Age (year) 40.4 ± 14.3 36.4 ± 13.5 42.1 ± 14.3a 47.3 ± 13.9b 46.4 ± 14.7c 48.8 ± 12.7d
Males (n, %) 122 (37.6) 38 (33.6) 70 (57.4) 34 (27.9) 39 (32.0) 10 (8.2)
Weight (kg) 84.8 ± 22.2 80.1 ± 18.8 89.1 ± 20.8a 86.2 ± 21.6b 86.0 ± 22.1c 86.3 ± 17.9
BMI (kg/m2) 32.0 ± 7.3 29.9 ± 6.6 33.9 ± 8.3a 33.2 ± 9.3b 33.4 ± 9.0c 32.8 ± 4.7
WC (cm) 103.9 ± 16.7 98.4 ± 16.5 108.1 ± 15.5a 105.9 ± 16.1b 107.3 ± 16.3c 107.0 ± 13.9d
M 105.2 ± 14.8 96.8 ± 15.3 110.1 ± 12.9a 108.6 ± 13.5b 110.2 ± 13.2c 110.9 ± 7.5d
F 103.1 ± 17.7 99.2 ± 17.2 106.8 ± 16.9a 104.1 ± 17.5 105.1 ± 18.1 104.0 ± 17.0
p 0.26 0.48 0.16 0.20 0.14 0.24
SBP (mmHg) 118.6 ± 15.5 111.7 ± 12.4 123.2 ± 16.3a 124.3 ± 16.0b 124.2 ± 16.0c 131.3 ± 17.0d
DBP (mmHg) 77.7 ± 10.0 74.1 ± 9.8 80.1 ± 9.7a 79.3 ± 8.7b 79.9 ± 8.8c 81.6 ± 8.7d
ALT (IU/L) 26.0 (20.0-41.0) 22 (17.0-31.0) 27.0 (22.0-51.0)a 29.0 (22.0-60.0)b 31.0 (23.0-49.0)c 30.0 (24.0-61.0)d
M 33.0 (23.7-62.7) 29.0 (22.0-38.5) 40.0 (26.0-80.0)a 39.5 (26.0-79.2)b 33.0 (24.0-79.0) 34.5 (28.0-65.5)
F 23.0 (19.0-32.0) 20.0 (16–28) 25.0 (20.0-34.0)a 25.0 (21.0-38.0)b 29.0 (23.0-44.0)c 27.0 (23.0-55.0)
p <0.001 0.001 <0.001 0.003 0.13 0.20
AST (IU/L) 25.0 (21.0-35.0) 23.0 (19.0-29.0) 26.0 (22.0-38.-0) 27.0 (22.0-41.5) 29.0 (23.0-42.0) 27.0 (23.0-45.0)
M 28.5 (22.0-41.2) 26.5 (21.0-34.5) 30.5 (23.0-48.2) 31.5 (25.0-47.2) 31.0 (23.0-45.0) 29.5 (23.7-45.7)
F 23.0 (20.0-3.5) 21.0 (180–27.2) 25.0 (21.0-32.0) 26.0 (22.0-37.0) 29.0 (22.2-37.5) 26.0 (22.0-50.5)
p <0.001 0.005 0.001 0.074 0.455 0.832













HDL-C (mg/dL) 37.7 ± 10.9 41.6 ± 12.6 34.7 ± 8.2a 37.1 ± 10.7b 35.2 ± 9.3c 30.6 ± 9.5d
M 32.5 ± 8.9 36.5 ± 10.5 30.9 ± 7.0a 32.1 ± 8.0 31.1 ± 8.1c 25.6 ± 4.4d
F 39.5 ± 11.0 44.4 ± 12.9 37.3 ± 8.0a 40.7 ± 11.0 38.1 ± 9.0c 35.6 ± 10.8d
p <0.001 0.003 <0.001 <0.001 0.001 0.01
Body fat (%) 38.1 ± 9.1 37.1 ± 9.5 39.2 ± 8.8a 38.2 ± 8.9 38.3 ± 8.8 38.8 ± 8.1
M 30.9 ± 7.2 28.6 ± 8.8 32.4 ± 5.9a 31.0 ± 6.3 31.8 ± 6.4 32.1 ± 4.6
F 42.4 ± 7.1 41.4 ± 6.5 43.6 ± 7.5a 43.0 ± 7.0 43.1 ± 7.2 44.0 ± 6.1
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
FG (mg/dL) 93.7 ± 13.6 85.7 ± 8.1 98.2 ± 14.8a 110.3 ± 13.0b 104.8 ± 16.4c 123.0 ± 19.2d
Fasting insulin (μlU/mL) 10.8 (6.9-15.4) 7.3 (5.2-11.6) 12.8 (8.1-17.9)a 13.7 (9.2-18.6)b 13.4 (8.5-19.9)c 14.8 (7.0-21.6)d
HOMA-2IR 1.4 (0.9-2.0) 1.0 (0.7-1.5) 1.7 (1.1-2.4)a 1.8 (1.2-2.4)b 1.8 (1.1-2.6)c 2.1 (0.9-3.0)d
ISI Matsuda 3.5 (2.3-5.5) 5.5 (3.9-8.5) 2.8 (1.9-4.4)a 2.5 (1.5-3.4)b 2.5 (1.5-3.6)c 2.1 (1.4-3.6)d
HIRI 36.9 ± 12.1 33.1 ± 12.0 39.4 ± 11.9a 38.6 ± 12.4b 37.6 ± 10.3c 36.3 ± 10.9
Data are expressed as mean ± SD (comparisons made with Student unpaired t-test), median [(interquartil range), comparisons made with Mann–Whitney U test],
or frequency [(%) comparisons made with the Pearson chi square] BMI = body mass index, WC=waist circumference, SBP = systolic blood pressure, DBP= diastolic
blood pressure, ALT = alanine aminotransferase, AST = aspartate aminotransferase, TC = total cholesterol, HDL-C = high density lipoprotein cholesterol, FG= fasting
glucose, HOMA2-IR =Homeostasis Model Assessment Insulin Resistance 2, ISI = Insulin Sensitivity Index, and HIRI = Hepatic Insulin Resistance Index.
a = p< 0.05 between subjects without metabolic abnormalities and MetS.
b = p< 0.05 between subjects without metabolic abnormalities and IFG.
c = p< 0.05 between subjects without metabolic abnormalities and IGT.
d = p< 0.05 between subjects without metabolic abnormalities and T2DM.
The total number of subjects is different of 324, because, 40% (n = 73) of subjects with MetS have IFG, 36% (n = 66) of subjects with MetS have IGT, and 11% of
subjects (n = 20) of subjects with MetS have DM2.
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HDL-C, TG and WC we identified certain parameters
with an independent association with HIRI levels
(Table 4). The first model, that included all subjects,showed an independent association between ALT levels
and HIRI (β= 0.07, t = 2.50, p = 0.013). In subjects with-
out metabolic abnormalities we did not find any inde-
pendent association between ALT levels and HIRI
Table 2 Characteristics of the subjects studied stratified by quartiles of HIRI (n = 324)










Age (years) 41.3 ± 15.5 43.5 ± 14.7 40.0 ± 12.7 36.9 ± 13.9 0.03
Sex male (n, %) 28 (35.4) 29 (35.3) 35 (42.6) 30 (37.0) 0.74
Weight (kg) 75.4 ± 15.3 80.3 ± 18.4 90.8 ± 20.0 92.4 ± 21.8 <0.001
BMI (kg/m2) 28.5 ± 6.2 30.5 ± 6.4 34.5 ± 8.9 34.8 ± 7.4 <0.001
WC (cm) 95.1 ± 15.1 101.3 ± 15.0 108.8 ± 15.2 110.1 ± 17.0 <0.001
Male 96.0 ± 10.9 103.2 ± 12.6 108.4 ± 14.7 111.9 ± 16.0 <0.001
Female 94.6 ± 17.0 100.3 ± 16.2 109.0 ± 15.7 109.0 ± 17.7 <0.001
SBP (mmHg) 113.9 ± 14.1 121.0 ± 16.8 118.2 ± 14.4 117.4 ± 12.8 0.007
DBP (mmHg) 74.1 ± 10.9 77.6 ± 8.0 79.7 ± 9.7 77.4 ± 10.2 0.001
ALT (IU/L) 21.0 (15.0-29.0) 24.0 (19.7-34.0) 27.0 (21.0-46.0) 32.0 (24.0-68.0) <0.001
Male 24.5 (15.5-40.2) 28.0 (23.0-36.0) 39.0 (26.0-61.0) 63.5 (31.0-93.0) <0.001
Female 20.0 (15.0-26.0) 23.0 (19.0-30.0) 24.0 (20.0-37.0) 27.0 (22.0-40.0) <0.001
AST (IU/L) 22.0 (19.0-29.0) 25.0 (21.0-31.0) 26.0 (21.0-37.0) 27.0 (22.5-45.5) 0.002
Male 24.5 (20.0-35.2) 28.0 (22.0-36.0) 29.0 (24.0-39.0) 38.5 (24.0-55.0) 0.026
Female 22.0 (19.0-27.0) 24.0 (20.5-29.0) 23.5 (19.0-34.2) 25.0 (21.0-36.0) 0.143
Cholesterol (mg/dL) 187.4 ± 39.5 190.2 ± 37.3 186.9 ± 36.5 191.0 ± 32.1 0.89
Triglycerides (mg/dL) 122.0 (81.5-166.0) 140.0 (95.0-204.2) 151.0 (114.2-204.0) 198.0 (148.5-348.5) <0.001
HDL-C (mg/dL) 40.3 ± 12.5 40.5 ± 11.2 34.9 ± 8.1 35.1 ± 10.1 <0.001
Male 32.8 ± 8.8 36.8 ± 11.5 36.1 ± 8.1 29.6 ± 6.4 0.03
Female 44.6 ± 12.3 42.4 ± 10.7 39.8 ± 10.9 36.8 ± 8.9 0.001
Body fat (%) 35.0 ± 9.5 37.0 ± 8.7 39.8 ± 9.1 40.4 ± 8.0 <0.001
Male 27.0 ± 6.8 29.0 ± 5.6 33.0 ± 7.8 33.9 ± 6.4 <0.001
Female 39.4 ± 7.8 41.4 ± 6.8 45.0 ± 6.3 43.1 ± 7.4 <0.001
Glucose (mg/dL) 88.8 ± 12.9 94.2 ± 14.6 96.5 ± 12.7 95.1 ± 12.9 0.002
Insulin (μlU/mL) 6.5 (4.5-8.2) 8.2 (6.3-12.0) 13.1 (9.2-16.0) 17.6 (13.1-24.5) <0.001
HOMA2-IR 0.8 (0.6-1.1) 1.1 (0.8-1.5) 1.7 (1.2-2.1) 2.3 (1.7-3.2) <0.001
ISI Matsuda 6.9 (5.0-9.7) 4.6 (3.2-6.0) 2.9 (2.1-3.9) 2.0 (1.3-2.6) <0.001
HIRI 23.4 ± 3.0 31.7 ± 2.1 39.0 ± 2.1 53.3 ± 9.5 <0.001
Data are expressed as mean ± SD, median (interquartil range), or frequency (%). Analyses were adjusted by gender. P values obtained of individual comparison
using the Pearson chi square for frequency variables, one-way ANOVA (normally distributed variables) or Kruskall–Wallis (skewed distribution variables) test.
BMI = body mass index, WC=waist circumference, SBP = systolic blood pressure, DBP= diastolic blood pressure, ALT = alanine aminotransferase, AST = aspartate
aminotransferase, HDL-C = high density lipoprotein cholesterol, HOMA2-IR =Homeostasis Model Assessment Insulin Resistance 2, ISI = Insulin Sensitivity Index, and
HIRI = Hepatic Insulin Resistance Index.
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that correspond to subjects with the MetS (model 3),
IFG (model 4), IGT (model 5), and T2DM (model 6) we
found an independent association between ALT and
HIRI levels (p < 0.05 in all models, Table 4). Because of
high collinearity between AST and ALT (r = 0.83,
p < 0.001), we made different regression models utilizing
AST instead of ALT. AST showed an independent asso-
ciation with HIRI (p < 0.05) in models: 1 (all subjects;
beta = 0.08; t = 2.47; p = 0.014), model 3 (MetS; beta =
0.09, t = 2.47, p = 0.014), model 5 (IGT; beta = 0.11;
t = 2.62; p = 0.011) and model 6 (T2DM; beta = 0.48;
t = 3.35; p = 0.005). In individuals without metabolic ab-
normalities (model 2; beta =−0.04; t =−0.41; p = 0.681)and with IFG (model 4; beta = 0.08; t = 1.61; p = 0.11) we
did not find any independent association between AST
levels and HIRI (Additional File 1: Table S1).
Discussion
ALT levels have been associated with insulin resistance,
the metabolic syndrome and the development of T2DM
[13-15]. The aim of this study was to evaluate the associ-
ation of serum ALT levels with surrogate markers of sys-
temic and hepatic insulin resistance in subjects with and
without impaired glucose metabolism. Since we excluded
subjects on hepatotoxic drugs, or with liver disease or
cirrhosis, this study suggests that ALT could be an indirect
parameter reflecting the presence of hepatic insulin
Figure 1 Comparison of HOMA2-IR, ISI Matsuda and HIRI with serum ALT levels. a. HOMA2-IR (n = 324, p < 0.001), and c. HIRI (n = 324,
p < 0.001) significantly increased within ALT levels, whereas b. ISI Matsuda (n = 324, p < 0.001), significantly decreased within ALT levels, in both
men and women. HOMA2-IR=Homeostasis Model Assessment for Insulin Resistance, ISI = Insulin Sensitivity Index, HIRI =Hepatic Insulin Resistance Index.
Gómez-Sámano et al. BMC Endocrine Disorders 2012, 12:16 Page 6 of 9
http://www.biomedcentral.com/1472-6823/12/16resistance in subjects with differing degrees of impaired
glucose metabolism. We observed that in subjects without
metabolic abnormalities, the association between ALT and
HIRI was not statistically significant. However, in subjects
with impaired glucose metabolism, or insulin resistance,
ALT levels were an independent marker of hepatic insulin
resistance as measured with HIRI. Measurement of ALT
might be helpful as an early marker of metabolic abnor-
malities. We focused on ALT because this liver enzyme is
more elevated in nonalcoholic steatohepatitis (NASH) than
AST [29]. Also the linear regression models demonstrated
that ALT levels showed association in all groups with
impaired glucose metabolism. In contrast, AST was not
statistically associated in the IFG group.
Initially, we identified several factors associated with a
lineal increment in HIRI levels. We found that weight,
BMI, WC, ALT, body fat percentage, insulin, andHOMA2-IR, increased progressively with higher quartiles
of HIRI. Moreover, HIRI correlated positively with WC,
ALT, TG, fasting glucose and insulin, HOMA2-IR; and
negatively with HDL-c and ISI Matsuda. Furthermore,
ALT was higher in men than women, an association that
has previously been reported [30-32]. Only two previ-
ous studies have evaluated the association between
ALT and hepatic IR; both of which used the euglycemic-
hyperinsulinemic clamp [13,32]. Vozarova and cols [13]
reported that higher ALT concentrations are associated
with obesity, whole-body- and hepatic-IR. Furthermore,
in a prospective observation, ALT levels were associated
with a decline in hepatic insulin sensitivity and the de-
velopment of type 2 diabetes. In our study, we used a
novel hepatic IR index derived from the OGTT that can
easily be applied in clinical practice. We found that HIRI
correlated positively with serum ALT levels (Table 3).
Table 3 Partial correlations of the HIRI with clinical and biochemical parameters




abnormalities (n = 113)
Metabolic syndrome
(n= 179)
IFG (n = 85) IGT (n= 91) T2DM (n= 23)
Variable r r r r r r
Weight 0.07 −0.17 0.13 0.09 0.24b 0.13
WC 0.15b 0.04 0.16b 0.12 0.20 −0.31
SBP 0.09 0.05 0.05 −0.15 0.02 −0.13
DBP 0.08 0.09 0.01 −0.21 0.03 −0.02
ALT 0.20a 0.03 0.22b 0.33a 0.37b 0.72a
AST 0.22a 0.12 0.19b 0.26b 0.38a 0.51b
Cholesterol 0.01 −0.17 0.001 0.02 0.10 0.19
Triglycerides 0.19a 0.05 0.13 0.19 0.16 0.31
HDL-C -0.15 -0.08 -0.08 -0.16 -0.05 0.21
Body fat 0.07 -0.03 0.10 0.01 0.19 0.09
Glucose 0.12b 0.16 0.03 0.01 0.09 0.29
Insulin 0.54a 0.63a 0.51a 0.56a 0.69a 0.81a
HOMA2-IR 0.53a 0.63a 0.51a 0.56a 0.69a 0.81a
ISI Matsuda -0.59a -0.60 -0.57a 0.61a 0.69a -0.84a
P Values obtained of individual comparison using Spearman (normally distributed variable) or Pearson (skewed distribution variables) bivariate correlation tests:
a = p< 0.001, b = p< 0.05. BMI = body mass index, WC=waist circumference, SBP = systolic blood pressure, DBP = diastolic blood pressure, ALT = alanine
aminotransferase, AST = aspartate aminotransferase, HDL-C = high density lipoprotein cholesterol, HOMA2-IR =Homeostasis Model Assessment Insulin Resistance 2,
ISI = Insulin Sensitivity Index, and HIRI = Hepatic Insulin Resistance Index. The total number of subjects is different from 324, because, 40% (n = 73) of subjects with
MetS have IFG, 36% (n= 66) of subjects with MetS have IGT, and 11% of subjects (n = 20) of subjects with MetS have DM2.
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that an increment in this enzyme could be related to un-
diagnosed hepatic insulin resistance. Hepatic lipotoxicity
caused by an oversupply of free fatty acids to the liver
results in excess hepatic triglyceride synthesis and an
intracellular accumulation of toxic lipid products that
impair insulin signaling and activate inflammatory path-
ways [33]. The adaptation to this metabolic stress
involves hepatic IR, dyslipidemia, steatohepatitis with
mitochondrial dysfunction, endoplasmic reticulum
stress, release of reactive oxygen species, and ultimately,
hepatocellular damage [34].
The liver damage related to insulin resistance pro-
gresses to cirrhosis in approximately 20% of subjects
with non-alcoholic steatohepatitis [35]. Therefore, early
identification of metabolic abnormalities could be useful
for initiating treatment and reducing the progression or
even reverting the problem. Accordingly, we propose
predicting the HIRI level using a single ALT measure-
ment. According to model 3 (subjects with MetS), for
each 10 IU/L of increment in ALT, the HIRI would in-
crease approximately 0.7 units. However, a higher incre-
ment in HIRI could be expected if the patient has more
severe impaired glucose metabolism. In subjects with
IFG that corresponds to subjects with greater hepatic
glucose production and hepatic IR [25], and in those
with IGT that corresponds to subjects with impaired
systemic IR [25] (models 4 and 5) for every 10 unitincrement in ALT, HIRI increased by 0.9 and 1.0 unit re-
spectively. In subjects with T2DM (model 6), an incre-
ment of 3 units of HIRI could be expected for the same
10 IU/L increment in ALT. This progressive increment
in ALT with worsening glucose metabolism, possibly
reflects how far along the patient is in the natural history
of T2DM. The degree of hepatic insulin resistance could
be predicted using the formula HIRI = constant + beta
(ALT level). The value of the constant and beta could be
obtained from Table 4, depending on the patient diagno-
sis. If the patient does not have a metabolic diagnosis
yet, we suggest using the information presented in
model 1. We cannot confirm the association between
ALT and fatty liver disease with the current design, how-
ever our hypothesis is that individuals with higher
plasma concentrations of ALT and/or higher levels of
HIRI could have an underlying liver disease that war-
rants further investigation. In addition, the benefit of
metformin treatment in improving HIRI was recently
reported by our group [36]. Similarly, another report has
shown that metformin reduces ALT levels [30]. Perhaps,
subjects identified with high normal or elevated serum
ALT levels, without any other known liver disease, could
benefit from metformin treatment to reduce hepatic in-
sulin resistance. However, this point warrants further in-
vestigation in prospective studies. It is important to
mention that our results could be potentially biased
since we included patients that had an in dication for
Table 4 Regression analysis of variables associated with
the HIRI
Variable β Standardized β T p value
Model 1 (all subjects, n=324)
Age −0.11 −0.13 −1.86 0.064
ALT 0.07 0.17 2.50 0.013
HDL-C −0.07 −0.05 −0.67 0.501
TG 0.009 0.114 1.60 0.111
WC 0.17 0.22 2.98 0.003
Model 2 (Subjects without metabolic abnormalities, n=113)
Age −0.05 −0.06 −0.57 0.569
ALT 0.005 0.009 0.08 0.933
HDL-C −0.04 −0.05 −0.49 0.623
TG 0.013 0.065 0.61 0.541
WC 0.17 0.25 2.40 0.018
Model 3 (Subjects with metabolic syndrome, n=179)
Age −0.11 −0.13 −1.86 0.064
ALT 0.07 0.17 2.50 0.013
HDL-C −0.07 −0.05 −0.67 0.501
TG 0.009 0.11 1.60 0.111
WC 0.17 0.22 2.98 0.003
Model 4 (Subjects with impaired fasting glucose, n=85)
Age −0.07 −0.08 −0.72 0.470
ALT 0.107 0.26 2.31 0.023
HDL-C −0.05 −0.05 −0.39 0.697
TG 0.01 0.08 0.68 0.496
WC 0.08 0.11 0.97 0.334
Model 5 (Subjects with impaired glucose tolerance, n=91)
Age −0.17 −0.24 −2.41 0.018
ALT 0.09 0.28 2.78 0.007
HDL-C 0.02 0.02 0.201 0.841
TG 0.008 0.06 0.66 0.507
WC 0.14 0.22 2.18 0.032
Model 6 (Subjects with type 2 diabetes, n=23)
Age 0.07 0.09 0.52 0.611
ALT 0.31 0.68 3.61 0.003
HDL-C 0.10 0.09 0.42 0.679
TG 0.01 0.15 0.75 0.463
WC −0.09 −0.11 −0.48 0.636
Parameters of model 1: Constant: 23.6, F = 7.20; r2 = 0.17, p = <0.001.
Parameters of model 2: Constant: 17.72, F = 1.43; r2 = 0.07, p = 0.221.
Parameters of model 3: Constant: 23.6, F = 7.20; r2 = 0.17, p < 0.001.
Parameters of model 4: Constant: 27.7, F = 2.81; r2 = 0.16, p = 0.02.
Parameters of model 5: Constant: 23.0, F = 5.94; r2 = 0.28, p = 0.001.
Parameters of model 6: Constant: 21.0, F = 3.26; r2 = 0.53, p = 0.037.
ALT = alanine aminotransferase, HDL-C = high density lipoprotein cholesterol,
TG = Triglycerides, WC=waist circumference, HIRI = Hepatic Insulin Resistance
Index.
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the 113 patients that had no metabolic abnormalities
we did not find any association between ALT and HIRI
(Table 3, r = 0.03, p = 0.744; Table 4, model 2, beta = 0.005,p=0.221). These results suggest that the increase in ALT
in our patients is related to the metabolic derangement.
This study has certain limitations. Firstly, the cross-
sectional design of our study does not allow us to con-
clude causality. Our results do not show that correction
of insulin resistance with medication, diet, or exercising
will improve ALT levels. Secondly, we used surrogate
markers of insulin resistance. The results presented here
should be confirmed in the clinical setting and studies
with a prospective design. We did not take into account
the amount of alcohol intake of the subjects in this study.
In addition, our patients were not evaluated with liver
ultrasound or gamma-glutamyl transpeptidase (GGT)
levels, the results of which would aid patient diagnosis.
Finally, these results can only be applied to similar indivi-
duals. Since ALT levels may differ by ethnic groups [37],
our results should be confirmed in different populations.
Conclusions
In conclusion, we found that ALT levels are independ-
ently associated with HIRI in subjects with the MetS,
IFG, IGT, and T2DM. The ALT value in these subjects
may be an indirect parameter to evaluate hepatic IR.
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